RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that data from a Phase 2a study of VT-1161, the Company’s lead novel, oral antifungal compound, will be presented at the American Podiatric Medical Association 2015 Annual Scientific Meeting, to be held from July 23-26, 2015, in Orlando, FL. In addition, the company will also provide an update on the ongoing RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation) study, a Phase 2b clinical trial of VT-1161 for the oral treatment of toenail fungal infection, also known as onychomycosis.
Help employers find you! Check out all the jobs and post your resume.
